SpectraScience Inc. (OTC: SCIE) offers a simplified yet highly effective way of diagnosing colorectal cancer early, when recovery rates are high. The company's WavSTAT Optical Biopsy System® uses light to diagnose tissue health.
According to the American Cancer Society, over 140,000 new cases of colorectal cancer are expected in the US this year alone. This dreaded disease is the second leading cause of cancer-related deaths in the US (after lung cancer), and the third most common cancer overall. Only 39% of colorectal cancers are detected at an early stage. SNNLive spoke with Michael Oliver, President and CEO of SpectraScience, Inc. at the LD Micro Invitational 2014 in Bel Air, CA.
“SpectraScience performs what are called optical biopsies. The traditional biopsy is cutting out tissues, sending it to a pathology lab and having a doctor or technician look at it to see if it might be cancerous,” begins Mr. Oliver. He continues, “What we do is we shine a light on human tissue, we can make the diagnostic decision whether or not that tissue is potentially cancerous or not without removing it from the body and we do it in about second.”
Mr. Oliver explains, “It’s really about reducing the total cost of healthcare and what we do is replace those very dangerous, those expensive physical pathologies with something that is safer for the patient, faster for the clinician and less expensive for the healthcare system.” For more information, check out their website at www.spectrascience.com
© 2017 Stock News Now
Supported by Superior Web Solutions